Invesco

Flow Carbon uses blockchain technology to put carbon offset credits on-chain, accelerating the creativity and scalability of climate change solutions. Flow Carbon is headquartered in New York, United States and was founded in 2021.

GeNeuro is a biotechnology company based in Plan-Les-Ouates, Switzerland, established in 2006. It specializes in developing therapeutic drugs for diseases linked to pathogenic proteins derived from human endogenous retroviruses, particularly focusing on nervous system diseases such as multiple sclerosis and schizophrenia. The company's lead product, GNbAC1, is a therapeutic monoclonal antibody aimed at treating multiple sclerosis, while temelimab is designed to neutralize a pathogenic protein associated with the HERV-W family. Additionally, GeNeuro is engaged in creating diagnostic tests to measure multiple sclerosis-related retrovirus-ENV proteins in patients, contributing to the understanding and management of these conditions.

Developer of a financial education platform intended to provide financial literacy and baking services to teenagers. The company's platform educates teens on how to make financial decisions by developing patterned behaviors in a supervised app experience, allowing the transfer of money, direct deposits, and payments, enabling teenagers to become financially literate and parents and teens to achieve financial freedom.

Swiggy is an on-demand food delivery platform that connects users with local restaurants, allowing them to order food conveniently through a mobile app. Founded in 2014 by Sriharsha Majety, Nandan Reddy, and Rahul Jaimini, the company is headquartered in Bangalore, Karnataka, India. Swiggy offers a comprehensive list of nearby restaurants and their menus, enabling users to track their orders in real-time. In addition to food delivery, Swiggy also provides services for picking up and dropping off various items, such as laundry and parcels, catering to both business clients and retail customers. The platform emphasizes speed and convenience, ensuring that users receive their food fresh and on time, often accompanied by discounts.

Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.

Pine Labs Private Limited is a technology company that operates a cloud-based unified point-of-sale (POS) platform designed for merchants across India, Southeast Asia, and the Middle East. The company provides a range of digital payment solutions and merchant commerce services, including Android-based smart POS devices and options for instant equated monthly installment (EMI) payments, loyalty programs, gift cards, and customer analytics. Pine Labs connects financial institutions and consumer brands, facilitating offline and online retail transactions and delivering customer insights for targeted sales strategies. Its platform supports over 350,000 POS terminals in more than 3,700 cities and towns, serving over 100,000 merchants across various sectors such as electronics, food and beverage, and fashion. The company also offers applications like myPlutus, which provides real-time transaction data, and Promozone, which aids in running promotional campaigns. Founded in 1998 and headquartered in Noida, India, Pine Labs has expanded its presence with offices in multiple Indian cities, as well as locations in Kuala Lumpur and Dubai.

Aumni is a data-driven investment management platform based in the United States that serves the venture capital industry. It offers a portfolio intelligence solution that helps venture capital firms enhance their operational efficiency and gain a competitive edge. Aumni's platform audits, analyzes, and visualizes key data from venture capital deal documents, extracting hundreds of data points to track critical insights, including investment rights, portfolio performance, and emerging investment trends. By converting complex deal data into a clear and error-free dataset, Aumni enables investors and venture firms to make informed strategic decisions and streamline their daily operations. The platform is designed for forward-thinking investment teams aiming to unlock and structure the vast amounts of untapped data within their portfolios.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Raymond Management is a full service property management company focused on helping investment property owners maximize the return on, and value of their real estate assets.

Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.

Godrej Properties, established in 1990, is the real estate development arm of the Godrej Group, based in Mumbai. The company focuses on developing a diverse range of residential, commercial, and township projects across India, covering an area of 10.3 million square meters in 12 cities. Committed to sustainability, all of its developments are certified green buildings, reflecting a philosophy of innovation and excellence that the Godrej Group has upheld for over 119 years. In addition to real estate, Godrej Properties also manages investments through funds like Godrej Office Fund II, which targets office assets in Mumbai. The firm aims to deliver high-quality and technologically advanced properties, enhancing the living and working environments in urban India.

Nubank issues, administrate, processes, and transfers payments related to post-paid credit cards and equity investment in other entities. It serves clients in Brazil. The company launched its proprietary loyalty rewards program ("Nubank Rewards"), as well as a digital account ("NuConta") that is already used by more than 17 million people. In Cristina Junqueira, David Velez, and Edward Wible founded EO2 Solucoes de Pagamento on May 6, 2013 that became Nubank in on June 25, 2013. It has its headquarters in São Paulo in Brazil.

Expert.ai specializes in cognitive computing software that utilizes artificial intelligence algorithms to understand and process written language. The company offers a range of products, including its flagship Cogito technology, which supports natural language understanding and machine learning to enhance business processes and decision-making. Key offerings include Cogito Discover for text analytics, Cogito for Claims to automate insurance management, and Cogito for Underwriting to improve risk assessment in insurance. Expert.ai also provides solutions for various sectors such as banking, insurance, life sciences, media, and public administration, along with tools for customer support and biomedical research. Founded in 1989 and headquartered in Modena, Italy, Expert.ai operates internationally, serving clients across Europe, the Americas, and the Middle East.

Clarksons offers its diverse and growing client base an unrivalled range of shipbroking services, sector research, on-hand logistical support and full investment banking capabilities in all key shipping and offshore sectors.

RedBlack Software, LLC specializes in providing technology solutions for investment advisors, wealth managers, broker-dealers, and financial institutions. Founded in 2006 and headquartered in Bedford, New Hampshire, the company offers a range of products focused on portfolio rebalancing and trade order management. Its flagship application, Rebalance Express, facilitates portfolio monitoring, rebalancing, and trading, while also supporting tax lot management, cash management, and compliance reporting. The company emphasizes a design philosophy driven by industry input, ensuring that its products are intuitive and accessible without compromising functionality. RedBlack's data-centric architecture is compatible with various data sources and supports major custodians, enabling rapid installation and user adoption. The software is built for scalability, allowing firms of varying sizes, from those managing $25 million to over $10 billion in assets, to efficiently manage thousands of accounts and generate extensive trade orders in a matter of minutes.

Grab Holdings Inc., based in Singapore, is a prominent mobile technology platform operating in Southeast Asia. Founded in 2012, the company offers a wide range of services, including ride-sharing through GrabTaxi and GrabCar, and food and grocery delivery. Grab also provides financial services, such as payments, consumer loans, and insurance, catering to both merchants and consumers. Its platform connects drivers and customers, generating revenue primarily through commissions from ride-sharing and food delivery services. Grab operates in eight countries, including Singapore, Indonesia, and Malaysia, where it holds a significant market share. The company has expanded its offerings to include various options for transportation and delivery, as well as a mobile wallet for seamless transactions. Grab continues to face competition from other regional players, such as Foodpanda and Gojek.

They are dedicated to serving the needs of our clients, who range from financial advisors and individual investors to corporations and endowments.

IntelliFlo Ltd. is a software company based in Kingston-upon-Thames, United Kingdom, established in 2004. It specializes in providing web-based business management solutions tailored for the financial services sector, including financial advisers, mortgage advisers, and various service providers. The company's flagship product, Intelligent Office, offers a comprehensive suite of features such as client management, document management, compliance tools, financial planning, and analytics. Additionally, it includes functionalities for lead management, task management, and income reconciliation, catering to both small and large businesses. IntelliFlo also provides product training services to enhance user proficiency. The company's focus on delivering practical, state-of-the-art software solutions aligns with the evolving needs of its clients in a dynamic market.

Alfred is an end-to-end resident experience and building management platform that is changing the way people live and transforming the real estate industry. Operating at the intersection of real estate and technology, Alfred builds intuitive, personal support into one of the most important spaces of our lives: our homes. Named one of the Top 50 Most Innovative Companies in the World by Fast Company in the urban development space, Alfred has been recognized in The New York Times, The Financial Times, and Wall Street Journal, as a pioneer in the on-demand economy, following their decision to hire Alfred Home Managers as W-2 employees (complete with benefits, training, and the ability to move up in the organization) and its support of local ecosystems and neighborhood businesses. Hello Alfred was founded in 2014 by Marcela Sapone and Jessica Beck, and is headquartered in New York, New York, United States.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.

Source is uniquely positioned to deliver highly liquid products that respond to the challenges and opportunities of the market They partner with some of the world’s largest investment houses and asset managers to create products that either offer exposure to new opportunities in the market or deliver existing strategies more effectively. They work together to ensure all of their products are efficient and transparent. On top of this, they work closely with some of the most well respected trading houses in Europe to ensure that their products are also priced as fairly as possible and are tradable throughout the day. Source is a global investment firm and one of the fastest growing European providers of exchange traded products (ETPs) By focusing on the ever-evolving needs of investors, they have grown assets under management to more than $19 billion (as at 30 July 2014) since their launch in April 2009, and during this time investors have traded more than $575 billion of Source’s products. They offer investors an efficient and transparent way to invest in equities, fixed income and commodities, as well as some alternative asset classes. Their ETPs are open-ended and domiciled in Dublin.

Glide Pharmaceutical Technologies Limited is a clinical-stage development company based in Abingdon, United Kingdom, specializing in solid dose formulations of therapeutics and vaccines. The company has developed the Solid Dose Injector (SDI) system, aimed at enhancing patient compliance for those self-administering long-term therapies. Its product pipeline includes solid dose formulations for medications such as octreotide, teriparatide, and vaccines for anthrax and influenza. Additionally, Glide is working on a novel non-invasive diagnostic technology focusing on prostate cancer, which seeks to identify clinically significant disease through a biochemical marker. Founded in 2001, the company was previously known as Caretek Medical Ltd. before rebranding in 2006.

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

NEXEON Limited operates as a battery materials and licensing company that develops silicon anodes for lithium-ion batteries. It offers silicon anode technology solutions for various applications, including consumer electronic, electronic vehicle, sustainable energy, aerospace, medical, and defense industries in the United Kingdom and internationally. The company was founded in 2006 and is based in Abingdon, United Kingdom with an additional office in Yokohama, Japan.

Jemstep Inc. offers online investment guidance and management services tailored for individual investors and financial advisors. Founded in 2008 and headquartered in Los Altos, California, the company leverages technology to provide ratings and comprehensive information on mutual funds and ETFs, including performance analysis and asset allocation. Jemstep's platform, Jemstep Advisor Pro, enhances the operations of investment advisors by automating client engagement, onboarding, and service processes, enabling them to attract more clients and manage assets more efficiently. The platform integrates with various service providers, allowing for a customizable business system that supports advisors in delivering enhanced value to their clients.

Gelesis, Inc. is a biotechnology company focused on developing therapies for gastrointestinal-related chronic diseases, particularly obesity and type 2 diabetes. Utilizing a mechanobiology technology platform, Gelesis creates innovative products aimed at weight management. Its lead product, Gelesis100, is an orally administered smart pill composed of hydrogel particles that expand in the gastrointestinal tract, promoting a feeling of fullness and aiding in calorie reduction. This product is designed to be safe, having materials recognized as safe by regulatory authorities. In addition to Gelesis100, the company has a pipeline of potential therapies targeting conditions such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic idiopathic constipation. Founded in 2006, Gelesis is based in Boston, Massachusetts.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.

Mereo is based in London and was founded in March 2015 to fund and develop novel, innovative specialist focused products from large pharmaceutical or biotechnology companies. Pharmaceutical companies face increasingly difficult choices in the allocation of internal resources to their drug development programs. With significant P&L constraints and rich pipelines it has become increasingly difficult for many companies to fully fund and advance development all of their drug candidates, especially beyond Phase 2. Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines. Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation. Mereo's focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the Company depends on the combination of its team's expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo's internal expertise is complemented by a unique partnership with a leading global CRO, ICON. Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo will rapidly progress each of the products through further value inflection points before partnering or divesting its products. The Company also has the option to directly commercialise products, for example in orphan disease indications.

Akamis Bio is a biotechnology company dedicated to developing innovative gene-based immuno-oncology therapies for cancer treatment. The company focuses on discovering and advancing a range of candidate therapies, including those utilizing its proprietary T-SIGn virus platform, which allows for systemic delivery while exerting localized effects within tumors. Akamis Bio aims to become a leader in cancer gene therapy, emphasizing the importance of creating medicines that provide tangible benefits to patients. The company is actively engaged in both early and clinical stage development of its therapies and seeks to establish strategic partnerships with other leaders in the immuno-oncology field to enhance its product offerings and accelerate the availability of its treatments.

SciFluor Life Sciences, Inc. is a drug discovery company based in Cambridge, Massachusetts, founded in 2011. The company focuses on developing therapeutics for various diseases, with a pipeline that includes small molecule compounds targeting areas such as neurology, ophthalmology, fibrosis, and inflammation. Notable products in development include SF0166, an integrin antagonist aimed at treating retinal diseases like age-related macular degeneration and diabetic macular edema through topical eye administration, and SF0034, a KCNQ2/3 activator designed to suppress neuronal hyperexcitability as an anti-epileptic treatment for partial-onset epilepsy. SciFluor utilizes a proprietary late-stage fluorination technology, licensed exclusively from Harvard University, which enhances drug properties such as metabolic stability, potency, bioavailability, and blood-brain-barrier penetration, allowing for fluorination of a wide array of organic compounds.

Luminex Trading & Analytics specializes in providing an equity trading platform designed to enhance the efficiency of institutional investors in sourcing block liquidity. The platform facilitates access to clean and natural block liquidity while significantly reducing trading costs. By engaging exclusively with venue-approved participants, Luminex ensures low-cost trading with minimal information leakage, thereby allowing traders to execute large block trades with reduced market impact. This focus on transparency and cost-effectiveness positions Luminex as a valuable resource for the institutional money management community.

Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Cell Medica is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease. Based on a number of academic studies, there is strong evidence that cellular immunotherapy can be used in a safe and effective manner to treat diseases ranging from infections to cancer. Cell Medica is both an R&D company developing new forms of cell therapies and a cell production/processing company providing clinical-grade cell formulations to hospitals for the treatment of patients.

Generator Hostel provides owns and operates hostels that provide accommodations (shared to private) for travelers.

Space Exploration Technologies is a space-transportation startup company founded by Elon Musk. SpaceX designs, manufactures, and launches advanced rockets and spacecraft. SpaceX develops crew and cargo capsules, engines, cryogenic tank structures, avionics, equipment, guidance, and control software. The company is developing the partially reusable launch vehicles Falcon 1 and Falcon 9. Founded in 2002, Space Exploration Technologies is headquartered in Hawthorne, California.

Alkermes Pharmaceutical Manufacturing and Global Biopharmaceutical Company

Ensurge Micropower specializes in the design and production of advanced ultrathin energy storage solutions, primarily focusing on solid-state lithium battery technology. This innovative approach allows for the development of rechargeable batteries characterized by high energy densities and extended product life, making them ideal for wearable devices, connected sensors, and various other applications. Founded in 2005 and headquartered in Oslo, Norway, the company leverages its expertise in printed electronics and roll-based manufacturing to create cost-effective solutions. By integrating hardware with smart packaging, Ensurge Micropower aims to advance the Internet of Things, facilitating seamless communication between brands and consumers. The company emphasizes enhancing consumer engagement and brand loyalty through efficient digital marketing strategies, positioning itself as a leader in the field of energy storage and smart technology solutions.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

infirst Healthcare Ltd. is a consumer healthcare company based in London, United Kingdom, founded in 2012. The company specializes in developing innovative versions of established over-the-counter medicines, focusing on solutions that can be launched within a 12-36 month timeframe. Notably, infirst has created a cocoa-flavored medicine aimed at treating cough and cold symptoms. As a spin-out from the UK-based drug discovery group SEEK, infirst leverages its intellectual property to develop breakthrough treatments for significant health issues. The company is led by CEO Manfred Scheske, who has extensive experience in the consumer healthcare sector, having previously overseen GSK's European Consumer Healthcare division and its North American operations.

Xeros Technology Group develops and commercializes innovative polymer-based technologies aimed at reducing water consumption in various cleaning applications across Europe and North America. The company focuses on creating alternatives to traditional aqueous cleaning methods, particularly for fabric and garment manufacturing as well as industrial and domestic laundry. Key products include XOrbs, which provide mechanical action to remove dirt and stains, XDrum for fabric manufacturing, and XFiltra, which de-waters filtered materials for easier disposal. Founded in 2013 and based in Rotherham, United Kingdom, Xeros leverages over 30 years of research from the University of Leeds to advance its "virtually waterless" laundry cleaning solutions, contributing to significant cost savings and improved environmental sustainability in the cleaning industry.

Glide Pharmaceutical Technologies Limited is a clinical-stage development company based in Abingdon, United Kingdom, specializing in solid dose formulations of therapeutics and vaccines. The company has developed the Solid Dose Injector (SDI) system, aimed at enhancing patient compliance for those self-administering long-term therapies. Its product pipeline includes solid dose formulations for medications such as octreotide, teriparatide, and vaccines for anthrax and influenza. Additionally, Glide is working on a novel non-invasive diagnostic technology focusing on prostate cancer, which seeks to identify clinically significant disease through a biochemical marker. Founded in 2001, the company was previously known as Caretek Medical Ltd. before rebranding in 2006.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.

Cell Medica is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease. Based on a number of academic studies, there is strong evidence that cellular immunotherapy can be used in a safe and effective manner to treat diseases ranging from infections to cancer. Cell Medica is both an R&D company developing new forms of cell therapies and a cell production/processing company providing clinical-grade cell formulations to hospitals for the treatment of patients.

Akamis Bio is a biotechnology company dedicated to developing innovative gene-based immuno-oncology therapies for cancer treatment. The company focuses on discovering and advancing a range of candidate therapies, including those utilizing its proprietary T-SIGn virus platform, which allows for systemic delivery while exerting localized effects within tumors. Akamis Bio aims to become a leader in cancer gene therapy, emphasizing the importance of creating medicines that provide tangible benefits to patients. The company is actively engaged in both early and clinical stage development of its therapies and seeks to establish strategic partnerships with other leaders in the immuno-oncology field to enhance its product offerings and accelerate the availability of its treatments.

Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed to replace the century old Mantoux skin test ( TST ).

Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.

Spin Memory, Inc. specializes in developing spin-transfer torque magnetoresistive random access memory (STT-MRAM) technologies and products. Founded in 2007 and based in Fremont, California, the company focuses on addressing the scaling and power challenges faced by memory devices. Its solutions are designed to replace on-chip SRAM and various non-volatile memories in both embedded and stand-alone applications. Spin Memory's proprietary orthogonal spin transfer MRAM technology, discovered by Professor Andrew Kent, offers significant advantages, including faster switching times, reduced power consumption, and improved scalability. The company aims to provide clients with cost-effective MRAM solutions that eliminate leakage power and overcome endurance and data retention limitations inherent in traditional memory technologies.

Centrify redefines security from a legacy static perimeter-based approach to protecting millions of scattered connections in a boundaryless hybrid enterprise. As the only industry-recognized leader in both Privileged Identity Management and Identity-as-a-Service, Centrify provides a single platform to secure each user’s access to apps and infrastructure through the power of identity services. This is Next Dimension Security in the Age of Access. Centrify is enabling over 5,000 customers, including over half the Fortune 50, to defend their organizations. To learn more visit www.centrify.com. The Breach Stops Here.

NEXEON Limited operates as a battery materials and licensing company that develops silicon anodes for lithium-ion batteries. It offers silicon anode technology solutions for various applications, including consumer electronic, electronic vehicle, sustainable energy, aerospace, medical, and defense industries in the United Kingdom and internationally. The company was founded in 2006 and is based in Abingdon, United Kingdom with an additional office in Yokohama, Japan.

Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and commercializing innovative products for respiratory diseases and allergies. The company operates through three key segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, which aid in the diagnosis and management of asthma, and offers Tudorza and Duaklir for COPD treatment. Duaklir combines aclidinium bromide and formoterol fumarate, administered via a breath-actuated inhaler. Additionally, Circassia is developing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly in the United States, the United Kingdom, China, Italy, and Germany, while also leveraging partnerships for international distribution. Circassia has a collaboration with AstraZeneca to promote its COPD treatments and holds rights to commercialize LungFit in the United States and China. Founded in 2006, Circassia continues to expand its pipeline, including novel treatments for allergies and COPD.

MaxWest Environmental Systems specializes in developing and operating waste-to-energy gasification facilities. The company utilizes a gasification and heat integration process to convert various types of waste, including biosolids, agricultural residues, construction and demolition debris, waste plastics, sludge, and wood waste, into renewable green energy. By transforming carbon-based products into usable energy, MaxWest aims to contribute to sustainable waste management solutions while providing an alternative energy source.

Akamis Bio is a biotechnology company dedicated to developing innovative gene-based immuno-oncology therapies for cancer treatment. The company focuses on discovering and advancing a range of candidate therapies, including those utilizing its proprietary T-SIGn virus platform, which allows for systemic delivery while exerting localized effects within tumors. Akamis Bio aims to become a leader in cancer gene therapy, emphasizing the importance of creating medicines that provide tangible benefits to patients. The company is actively engaged in both early and clinical stage development of its therapies and seeks to establish strategic partnerships with other leaders in the immuno-oncology field to enhance its product offerings and accelerate the availability of its treatments.

Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and commercializing innovative products for respiratory diseases and allergies. The company operates through three key segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, which aid in the diagnosis and management of asthma, and offers Tudorza and Duaklir for COPD treatment. Duaklir combines aclidinium bromide and formoterol fumarate, administered via a breath-actuated inhaler. Additionally, Circassia is developing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly in the United States, the United Kingdom, China, Italy, and Germany, while also leveraging partnerships for international distribution. Circassia has a collaboration with AstraZeneca to promote its COPD treatments and holds rights to commercialize LungFit in the United States and China. Founded in 2006, Circassia continues to expand its pipeline, including novel treatments for allergies and COPD.

Chelsio Communications, Inc. is a technology company that specializes in high-performance networking and storage solutions. Founded in 1997 and headquartered in Sunnyvale, California, with a design center in Bengaluru, India, Chelsio develops both hardware and software to address the demands of virtualized enterprise data centers, cloud service installations, and cluster computing environments. Its product offerings include Unified Wire Ethernet network adapter cards, unified storage software, high-performance storage gateways, unified management software, and bypass cards, among others. The company also provides protocol engines and server adapters designed for convergence networks, facilitating efficient traffic management over Ethernet. Chelsio markets its products through a network of distributors, integrators, and resellers, serving customers both domestically and internationally.

BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovative approach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery.

LogLogic offers a scalable log and security intelligence platform designed for both enterprise and cloud environments. With a customer base exceeding 1,300, the company enables organizations to collect and analyze vast amounts of data generated by their IT systems, totaling over 1,000 Petabytes. Its solutions cater to Security, IT Operations, and Compliance professionals, providing them with actionable insights to proactively identify issues and make informed decisions while ensuring compliance with various regulations. LogLogic's products facilitate real-time log analysis, enhancing network stability and security by translating raw data into meaningful information that helps administrators understand network activities and respond effectively.

ConSentry Networks, founded in 2003 and based in Milpitas, California, specializes in delivering intelligent control solutions that help organizations adapt to modern business practices, such as outsourcing and establishing partnerships. The company's technology has been adopted by clients worldwide, facilitating efficient management of resources and collaboration. ConSentry has garnered financial backing from notable investors, including Accel Partners, DAG Ventures, INVESCO Private Capital, and Translink Capital.

At NovaSys Health they value your participation as a contracted provider. Roughly 11,000 providers in this region and over 4,300 providers in Arkansas have contracted with NovaSys Health making it one of the largest health plans in Arkansas. They take pride in the relationships that they have cultivated with providers.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Touchdown Technologies, Inc. specializes in the design, manufacture, and support of advanced Micro-Electro-Mechanical Systems (MEMS) probe cards. The company offers products such as the ACCU-TORQ probe, a torsional contactor, and GIGA-TORQ probe cards specifically for DRAM applications. These products are tailored to meet the production wafer test requirements of semiconductor manufacturers globally. Founded in 2003 and based in Baldwin Park, California, Touchdown Technologies aims to reduce wafer test costs through innovative technologies that enhance the efficiency of highly parallel probe cards.

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and commercializing innovative products for respiratory diseases and allergies. The company operates through three key segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, which aid in the diagnosis and management of asthma, and offers Tudorza and Duaklir for COPD treatment. Duaklir combines aclidinium bromide and formoterol fumarate, administered via a breath-actuated inhaler. Additionally, Circassia is developing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly in the United States, the United Kingdom, China, Italy, and Germany, while also leveraging partnerships for international distribution. Circassia has a collaboration with AstraZeneca to promote its COPD treatments and holds rights to commercialize LungFit in the United States and China. Founded in 2006, Circassia continues to expand its pipeline, including novel treatments for allergies and COPD.

Chelsio Communications, Inc. is a technology company that specializes in high-performance networking and storage solutions. Founded in 1997 and headquartered in Sunnyvale, California, with a design center in Bengaluru, India, Chelsio develops both hardware and software to address the demands of virtualized enterprise data centers, cloud service installations, and cluster computing environments. Its product offerings include Unified Wire Ethernet network adapter cards, unified storage software, high-performance storage gateways, unified management software, and bypass cards, among others. The company also provides protocol engines and server adapters designed for convergence networks, facilitating efficient traffic management over Ethernet. Chelsio markets its products through a network of distributors, integrators, and resellers, serving customers both domestically and internationally.

POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques

BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovative approach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery.

Cast Iron Systems, Inc. specializes in providing software-as-a-service integration appliances tailored for large and midsize companies. The company offers the iA3000 application integration appliance, which delivers network computing solutions and preconfigured options for both enterprise and on-demand applications. These solutions enable users to connect with specific applications and facilitate integration processes, particularly for SAP and Oracle systems. In addition to its hardware and software offerings, Cast Iron Systems provides consulting, technical support, and educational services to enhance user experience and operational efficiency. Founded in 2001 and based in Mountain View, California, the company was previously known as IronHide Corporation.

AccountNow is a financial services company that specializes in providing prepaid card solutions for approximately 40 million consumers in the United States who lack traditional banking relationships or established credit. By offering alternatives to conventional checking accounts, AccountNow enables these individuals to access essential financial and payment systems. The company's offerings include Visa prepaid cards and various bill payment services, all designed to help consumers manage their finances more effectively. AccountNow's prepaid cards are issued by The Bancorp Bank or MetaBank, allowing them to be used wherever Visa or MasterCard is accepted. This positions AccountNow as a valuable resource for those seeking financial services outside of traditional banking.

Antenova, Ltd. specializes in the design and supply of standard and custom antennas and radio frequency antenna modules. Founded in 1999 and headquartered in Stow-cum-Quy, United Kingdom, the company serves a diverse range of applications, including mobile handsets, adapters, portable devices, laptop computers, and various wireless devices. Antenova is recognized as a leading provider of high-performance antennas specifically for wireless machine-to-machine (M2M) and consumer electronic devices. The company has design, sales, and support centers in Taipei, Taiwan; Chicago, Illinois; and Shanghai, China, alongside manufacturing operations located in Taiwan and China.

Centrify redefines security from a legacy static perimeter-based approach to protecting millions of scattered connections in a boundaryless hybrid enterprise. As the only industry-recognized leader in both Privileged Identity Management and Identity-as-a-Service, Centrify provides a single platform to secure each user’s access to apps and infrastructure through the power of identity services. This is Next Dimension Security in the Age of Access. Centrify is enabling over 5,000 customers, including over half the Fortune 50, to defend their organizations. To learn more visit www.centrify.com. The Breach Stops Here.

Celoxica Limited, based in Abingdon, United Kingdom, provides hardware-accelerated market data access and order execution solutions aimed at the financial services industry. Founded in 1996, the company specializes in ultra-low latency trading services, catering to the advanced trading community, including trading firms and banks engaged in high-frequency trading, market making, liquidity provision, algorithmic trading, and smart order routing. Celoxica offers a range of market data feed handlers covering major U.S. and European equities, options, futures, and foreign exchange markets. The company facilitates seamless connectivity for brokers and clients by managing inbound FIX, credit checks, and outbound native protocols to execution venues. With additional offices in Chicago and New York, Celoxica remains focused on meeting the growing demands for speed and efficiency in electronic trading.

Cortina Systems is a prominent supplier of intelligent communication solutions, specializing in advanced port processing and connectivity across various market segments, including Core, Metro, Access, and Enterprise. The company focuses on high-speed analog-digital integration, offering a diverse range of products designed to meet customer demands for performance, density, and flexibility. By understanding and anticipating client needs, Cortina Systems aims to facilitate faster time-to-market and enhance revenue opportunities for its customers. Through continuous innovation, the company is committed to developing foundational technologies that support the evolution of new service generations in the communications semiconductor sector.

LipoScience, based in Raleigh, North Carolina, specializes in developing in vitro diagnostic tests utilizing nuclear magnetic resonance (NMR) technology. The company's flagship product, the NMR LipoProfile test, quantifies low density lipoprotein particles (LDL-P) in blood samples, offering crucial insights for physicians and patients to tailor heart disease risk management. With more than 8 million tests ordered, LipoScience is at the forefront of personalized diagnostics, providing actionable data that enhances patient care and treatment strategies.

ConSentry Networks, founded in 2003 and based in Milpitas, California, specializes in delivering intelligent control solutions that help organizations adapt to modern business practices, such as outsourcing and establishing partnerships. The company's technology has been adopted by clients worldwide, facilitating efficient management of resources and collaboration. ConSentry has garnered financial backing from notable investors, including Accel Partners, DAG Ventures, INVESCO Private Capital, and Translink Capital.

Cast Iron Systems, Inc. specializes in providing software-as-a-service integration appliances tailored for large and midsize companies. The company offers the iA3000 application integration appliance, which delivers network computing solutions and preconfigured options for both enterprise and on-demand applications. These solutions enable users to connect with specific applications and facilitate integration processes, particularly for SAP and Oracle systems. In addition to its hardware and software offerings, Cast Iron Systems provides consulting, technical support, and educational services to enhance user experience and operational efficiency. Founded in 2001 and based in Mountain View, California, the company was previously known as IronHide Corporation.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, focused on developing innovative therapeutics for neurological disorders. The company's clinical pipeline includes several product candidates targeting epilepsy, such as XEN496 and XEN1101, both Kv7 potassium channel modulators currently in Phase II trials, and XEN901, a selective Nav1.6 sodium channel inhibitor in Phase I trials. Additionally, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase I trials. Xenon utilizes a proprietary discovery platform, known as Extreme Genetics, to identify genetic insights from families with severe phenotypes, enabling the development of novel medicines for both orphan and more common diseases. The company has established a collaboration with Neurocrine Biosciences to advance first-in-class treatments for epilepsy, highlighting its commitment to addressing unmet medical needs in the field of neurology.

Touchdown Technologies, Inc. specializes in the design, manufacture, and support of advanced Micro-Electro-Mechanical Systems (MEMS) probe cards. The company offers products such as the ACCU-TORQ probe, a torsional contactor, and GIGA-TORQ probe cards specifically for DRAM applications. These products are tailored to meet the production wafer test requirements of semiconductor manufacturers globally. Founded in 2003 and based in Baldwin Park, California, Touchdown Technologies aims to reduce wafer test costs through innovative technologies that enhance the efficiency of highly parallel probe cards.

Celoxica Limited, based in Abingdon, United Kingdom, provides hardware-accelerated market data access and order execution solutions aimed at the financial services industry. Founded in 1996, the company specializes in ultra-low latency trading services, catering to the advanced trading community, including trading firms and banks engaged in high-frequency trading, market making, liquidity provision, algorithmic trading, and smart order routing. Celoxica offers a range of market data feed handlers covering major U.S. and European equities, options, futures, and foreign exchange markets. The company facilitates seamless connectivity for brokers and clients by managing inbound FIX, credit checks, and outbound native protocols to execution venues. With additional offices in Chicago and New York, Celoxica remains focused on meeting the growing demands for speed and efficiency in electronic trading.

Cortina Systems is a prominent supplier of intelligent communication solutions, specializing in advanced port processing and connectivity across various market segments, including Core, Metro, Access, and Enterprise. The company focuses on high-speed analog-digital integration, offering a diverse range of products designed to meet customer demands for performance, density, and flexibility. By understanding and anticipating client needs, Cortina Systems aims to facilitate faster time-to-market and enhance revenue opportunities for its customers. Through continuous innovation, the company is committed to developing foundational technologies that support the evolution of new service generations in the communications semiconductor sector.

Centrify redefines security from a legacy static perimeter-based approach to protecting millions of scattered connections in a boundaryless hybrid enterprise. As the only industry-recognized leader in both Privileged Identity Management and Identity-as-a-Service, Centrify provides a single platform to secure each user’s access to apps and infrastructure through the power of identity services. This is Next Dimension Security in the Age of Access. Centrify is enabling over 5,000 customers, including over half the Fortune 50, to defend their organizations. To learn more visit www.centrify.com. The Breach Stops Here.

ConSentry Networks, founded in 2003 and based in Milpitas, California, specializes in delivering intelligent control solutions that help organizations adapt to modern business practices, such as outsourcing and establishing partnerships. The company's technology has been adopted by clients worldwide, facilitating efficient management of resources and collaboration. ConSentry has garnered financial backing from notable investors, including Accel Partners, DAG Ventures, INVESCO Private Capital, and Translink Capital.

SkyPilot Networks is a prominent provider of carrier-class broadband wireless equipment, specializing in solutions that facilitate cost-effective network services for service providers, municipalities, and public safety agencies. The company offers a patented multi-hop point-to-multipoint architecture that enhances the performance of high-gain directional antennas to improve reach, reduce interference, and optimize spectral efficiency. This technology enables the rapid deployment of various services, including last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. SkyPilot's product lineup includes the SkyPilot Connector Mini and SkyPilot Connector Pro, which provide economical customer premises equipment for long-range connectivity, along with the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record of scalability and reliability, SkyPilot has successfully delivered units to customers in over 50 countries. The company is headquartered in Santa Clara, California.

Arcot Systems, Inc. specializes in authentication and digital signing solutions designed to protect and verify the digital identities of cardholders and merchants. Founded in 1997 and headquartered in Sunnyvale, California, with a technology center in Bangalore, India, the company offers a range of products, including TransFort for Issuers and Merchants, which facilitate secure authentication processes; RiskFort, which addresses real-time fraud prevention; and SignFort, which streamlines document signing and approval. Additional solutions include WebFort and ArcotID for software-based authentication, as well as A-OK On-Demand for enhanced security in authentication. Arcot Systems caters to various sectors, including financial institutions, pharmaceutical companies, and e-commerce platforms, helping them mitigate online fraud and identity theft while ensuring compliance with regulatory standards.

Cast Iron Systems, Inc. specializes in providing software-as-a-service integration appliances tailored for large and midsize companies. The company offers the iA3000 application integration appliance, which delivers network computing solutions and preconfigured options for both enterprise and on-demand applications. These solutions enable users to connect with specific applications and facilitate integration processes, particularly for SAP and Oracle systems. In addition to its hardware and software offerings, Cast Iron Systems provides consulting, technical support, and educational services to enhance user experience and operational efficiency. Founded in 2001 and based in Mountain View, California, the company was previously known as IronHide Corporation.

GENBAND US LLC is a global provider of real-time communications software solutions tailored for service providers, enterprises, independent software vendors, and developers. Established in 1999 and based in Frisco, Texas, the company offers a diverse range of products, including telephony application servers that support voice, video, instant messaging, and collaboration across various devices and networks. Its intelligent messaging solutions enable unified communication services, while IP gateway and session border controller products ensure secure and reliable connectivity for both fixed and mobile networks. GENBAND also specializes in cloud-enabled platforms, network functions virtualization, and media gateways that enhance communication efficiency and productivity. As a subsidiary of Sonus Networks, GENBAND continues to focus on transforming and improving communication networks worldwide.

WhereNet Corporation offers wireless solutions for tracking and managing enterprise assets. I WhereNet provides an integrated wireless infrastructure for real-time location, messaging, and telemetry applications, including WhereLAN, a cellular network of locating access points, transmit devices; WhereLAN LOS, a network of tag transmission receivers which perform locations calculations, database functions, and systems management; WhereTag III, a low-powered active radio frequency transmitters associated with an asset; WhereTag IV, an asset tag, which can be configured to match specific location application requirements; WhereCall, a wireless messaging system used for parts replenishment in industrial manufacturing; and WherePort, a magnetic exciter that extends the functionality of WhereTags. The company also offers Visibility Software Server, a set of software development tools for integrating WhereNet, customer, and third-party applications. The company was founded in 1997 and is headquartered in Santa Clara, California. As of January 25, 2007, WhereNet Corporation operates as a subsidiary of Zebra Technologies Corp.

Confluent Photonics Corporation is developing passive and active DWDM optical components for the telecommunications industry based on silicon-on-insulator (SOI) semiconductor fabrication techniques. The use of SOI along with the CMOS fabrication infrastructure developed to process SOI enables cost-effective high volume optical telecom component solutions for the access, metropolitan and long haul telecom markets. The compatibility of Confluent optical designs and manufacturing techniques with CMOS fabrication also provides a pathway for the future integration of optics and electronics on the same telecommunications chip. Current optical telecommunication product technologies and designs result in miniaturized optical lab benches lacking thermal and mechanical robustness. In contrast, Confluent is designing and fabricating Telcordia-compliant optical chip components for the automated manufacture of integrated optical circuits. These components are designed to be insensitive to their environment. Using semiconductor-manufacturing techniques provides built in optical alignment, high volume production and low cost.

LipoScience, based in Raleigh, North Carolina, specializes in developing in vitro diagnostic tests utilizing nuclear magnetic resonance (NMR) technology. The company's flagship product, the NMR LipoProfile test, quantifies low density lipoprotein particles (LDL-P) in blood samples, offering crucial insights for physicians and patients to tailor heart disease risk management. With more than 8 million tests ordered, LipoScience is at the forefront of personalized diagnostics, providing actionable data that enhances patient care and treatment strategies.

VIEO provides innovative application service level management solutions for ensuring business certainty. These solutions provide end-to-end visibility of Microsoft web-based and Citrix-based application infrastructures and pinpoint resource problems that impact service levels. Using VIEO solutions, IT organizations can improve service delivery while reducing costs and complexity. VIEO's awards include Computerworld's 2004 Innovative Technology Award and InfoWorld's 2004 Systems Management Product of the Year. Led by IT visionary and successful serial entrepreneur Bob Fabbio, VIEO is headquartered in Austin, Texas.

SkyPilot Networks is a prominent provider of carrier-class broadband wireless equipment, specializing in solutions that facilitate cost-effective network services for service providers, municipalities, and public safety agencies. The company offers a patented multi-hop point-to-multipoint architecture that enhances the performance of high-gain directional antennas to improve reach, reduce interference, and optimize spectral efficiency. This technology enables the rapid deployment of various services, including last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. SkyPilot's product lineup includes the SkyPilot Connector Mini and SkyPilot Connector Pro, which provide economical customer premises equipment for long-range connectivity, along with the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record of scalability and reliability, SkyPilot has successfully delivered units to customers in over 50 countries. The company is headquartered in Santa Clara, California.

StarVox products are sold and serviced through major solution providers such as Hewlett Packard as a complete, factory-integrated IP telephony solution for service providers. The HP/StarVox Next Generation Telephony Solution combines StarVox software with HP's Open Call Multi Controller application platforms and Cisco Powered Network equipment, making it a carrier-grade, industry-standard solution that will allow a full range of value-added services and upgrades

2Wire, based in San Jose, California, specializes in providing broadband service products tailored for telecommunications companies. The company develops integrated solutions designed to enhance broadband service and content delivery throughout homes and small offices. Leveraging its expertise in both software and hardware, 2Wire enables users to maximize the advantages of broadband connectivity. Its offerings include residential gateways, multi-service media platforms, intelligent home servers, and remote management systems, all aimed at facilitating a seamless experience for both consumers and service providers. Additionally, 2Wire supports global telecom carriers with platforms that enable the delivery and management of voice, data, and media services, as well as providing customer support through call centers.

GENBAND US LLC is a global provider of real-time communications software solutions tailored for service providers, enterprises, independent software vendors, and developers. Established in 1999 and based in Frisco, Texas, the company offers a diverse range of products, including telephony application servers that support voice, video, instant messaging, and collaboration across various devices and networks. Its intelligent messaging solutions enable unified communication services, while IP gateway and session border controller products ensure secure and reliable connectivity for both fixed and mobile networks. GENBAND also specializes in cloud-enabled platforms, network functions virtualization, and media gateways that enhance communication efficiency and productivity. As a subsidiary of Sonus Networks, GENBAND continues to focus on transforming and improving communication networks worldwide.

Ishoni Networks develops broadband engines for residential and business customers.

EndPoints Inc. is a fabless semiconductor company that provides controller chips used in mass-market consumer products that capture and display video and still digital images across the internet and other networks. The company’s products control the operation of inexpensive digital video and still cameras that can connect to the Internet. These controller chips process and communicate the images that are captured and digitized by CMOS image sensor chips and are then sent through one of the company’s interfaces (USB, 1394, Ethernet, etc.) to a PC.

Confluent Photonics Corporation is developing passive and active DWDM optical components for the telecommunications industry based on silicon-on-insulator (SOI) semiconductor fabrication techniques. The use of SOI along with the CMOS fabrication infrastructure developed to process SOI enables cost-effective high volume optical telecom component solutions for the access, metropolitan and long haul telecom markets. The compatibility of Confluent optical designs and manufacturing techniques with CMOS fabrication also provides a pathway for the future integration of optics and electronics on the same telecommunications chip. Current optical telecommunication product technologies and designs result in miniaturized optical lab benches lacking thermal and mechanical robustness. In contrast, Confluent is designing and fabricating Telcordia-compliant optical chip components for the automated manufacture of integrated optical circuits. These components are designed to be insensitive to their environment. Using semiconductor-manufacturing techniques provides built in optical alignment, high volume production and low cost.

Calient provides high-density 3D MEMS (Micro-Electro-Mechanical Systems) optical circuit switching for software-defined networks and data centers. Its optical circuit switching technology is used by service providers, cloud computing, content delivery, and government networks. This offers businesses with adaptive photonic switching systems that enable dynamic optical layer optimization in software-defined networks and data centers. The company’s 3D-MEMS switches enable dynamic optical-layer sharing, optimization, and automation of high-performance test, compute, and network resources in data centers, optical transport networks, and DevOps test automation facilities. Calient Technologies was established in 1999 and is headquartered in Goleta, California.

Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, Russia, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in London, United Kingdom.